Skip to main content

Table 1 Numbers of patients participating in the ATTAIN, ASSURE, ARRIVE, and ACTION studies who were taking one csDMARD in combination with abatacept or placebo

From: Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting

 

Number of patients

 

ATTAIN

ASSURE

ARRIVE

ACTION

Total

ABA + MTX

175

535

490

1182

2382

PBO + MTX

89

243

–

–

332

ABA + HCQ

11

35

49

57

152

PBO + HCQ

2

33

–

–

35

ABA + SSZ

10

36

32

45

123

PBO + SSZ

4

10

–

–

14

ABA + AZA

4

10

30

15

59

PBO + AZA

1

9

–

–

10

ABA + LEF

17

62

65

253

397

PBO + LEF

7

29

–

–

36

  1. ABA abatacept, AZA azathioprine, csDMARD conventional synthetic disease-modifying antirheumatic drug, HCQ hydroxychloroquine, LEF leflunomide, MTX methotrexate, PBO placebo, SSZ sulfasalazine
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us